Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
about
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancerAssociation of cetuximab with adverse pulmonary events in cancer patients: a comprehensive reviewEpidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancerAmplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancerMarkers of resistance to anti-EGFR therapy in colorectal cancerThe relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactoseMolecular origins of cancer: Molecular basis of colorectal cancerPhase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liverOverexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cellsPerioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trialPhase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancerSurgical resection of hepatic metastases from colorectal cancer: a systematic review of published studiesEGFR targeted therapy in non-small cell lung cancer: potential role of cetuximabAssessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarrayA prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapyPrognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer.Adding pharmacogenomics to the development of new marine-derived anticancer agentsMechanisms of drug resistance in colon cancer and its therapeutic strategiesPredictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of OptionsNew trends in molecular and cellular biomarker discovery for colorectal cancerCurrent targeted therapies in the treatment of advanced colorectal cancer: a reviewAdvances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerMolecular testing to optimize therapeutic decision making in advanced colorectal cancerAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraPrognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenibBiomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRASPharmacologic resistance in colorectal cancer: a reviewNovel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialMolecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancerClinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancerHepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancerTumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastasesBiomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancerAdjuvant chemotherapy for rectal cancer: Is it needed?Therapeutic strategy in unresectable metastatic colorectal cancer: an updated reviewThe Insulin/IGF System in Colorectal Cancer Development and Resistance to TherapyEffectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysisThe role of Reg IV in colorectal cancer, as a potential therapeutic targetEvaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imagingNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
P2860
Q21142734-5A6DF45B-F468-4354-9D74-5BF52D559FF4Q21198850-B7408669-4D01-47FE-8281-43CBFC14758DQ24243806-A84828BE-A103-4829-BC52-438173E8B12AQ24563539-368F0793-5715-44EC-8206-154034E10C33Q24598640-BF5769CF-E086-4952-A398-FAA2B138BAF3Q24604244-2368D803-7374-41CD-B286-A1252D078388Q24617331-48BB5B29-4551-4BEB-ACB7-270DDBEFBC60Q24633957-6F745441-1F54-4519-B996-7583B0535D83Q24646343-9B2BFB62-8846-4A26-A585-0B2F1BF8BCAEQ24647888-9A8763E9-5324-4B51-86A7-CC37ED48FE03Q24649684-C5B43D3C-E181-4117-926E-6722D947B6D6Q24651894-1B8722AC-DB02-42A4-B69E-AC20C94FAE37Q24652337-08A84EBF-05D5-4B11-999C-E4BD49270161Q24675853-AD687FA4-1A88-4138-9DF5-BB76D2B88ADAQ24811929-5ED8AFAB-AAED-4266-A79F-4DD6787751D8Q24812583-D2A4BB1A-2B17-418F-A69A-3479DF907F09Q25254985-77632666-E649-49FA-AB6B-CF1ECEBCA4BFQ26738528-9D4F889F-0945-45EB-BC73-786433CB2E28Q26738655-DEA49592-25BB-4940-8780-9540470D6269Q26739049-DCE61E63-CFA4-4210-B8E0-7C7EDFC9794DQ26740067-2ED90085-07F1-4184-AD82-7A8D6D0AD979Q26748924-539BA48D-E9A7-476F-9EE9-AF9427C7815EQ26749012-573D56C0-0982-4307-9E0E-570B1436389CQ26751344-DCE7AA97-011F-466F-B115-7E842CF255ACQ26765210-EACF5F32-715F-4CC5-8B61-23A32F757FDAQ26766535-FC6B27B1-B4BB-4EF3-AA86-409181E80582Q26769850-ABA4EC25-E228-4170-895A-91BC216F379EQ26769884-AA684970-8E56-4E58-A81A-DC5045B114CDQ26769935-8A14BB20-E87C-4D83-B7B4-9524A6C868D6Q26769958-CD14A90E-CA62-4B42-851D-1F0AC92FF84EQ26772267-D531C102-9D06-4623-A87F-83B60DAEBB39Q26772274-B52D76FC-790C-404C-8F31-02790B874FFDQ26774605-164CA03D-D562-45B3-8A1F-4C2EAF450B16Q26775099-6B6E92B9-ADAE-4246-B62E-82E08FCB12C3Q26775522-54861E17-5FFE-4E7D-8F33-9B10E737A4E8Q26777125-21992AE8-188B-4274-82FB-C42C5B9BACDAQ26777704-E7507670-7486-4AB8-B9CE-DF9551794876Q26777750-70A71368-6652-4C55-99F8-6C49ECF6CEF0Q26783895-1FE52FAB-898C-4D95-924C-2D50D472BFF9Q26796348-18C2F150-ADA4-41E4-A628-54001B8F8B5C
P2860
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Cetuximab monotherapy and cetu ...... y metastatic colorectal cancer
@ast
Cetuximab monotherapy and cetu ...... y metastatic colorectal cancer
@en
type
label
Cetuximab monotherapy and cetu ...... y metastatic colorectal cancer
@ast
Cetuximab monotherapy and cetu ...... y metastatic colorectal cancer
@en
prefLabel
Cetuximab monotherapy and cetu ...... y metastatic colorectal cancer
@ast
Cetuximab monotherapy and cetu ...... y metastatic colorectal cancer
@en
P2093
P3181
P356
P1476
Cetuximab monotherapy and cetu ...... y metastatic colorectal cancer
@en
P2093
Andreas Harstrick
Armando Santoro
Chris Verslype
Danny Bets
David Khayat
Eric Van Cutsem
Harry Bleiberg
Matthias Mueser
Yves Humblet
P304
P3181
P356
10.1056/NEJMOA033025
P407
P577
2004-07-01T00:00:00Z